Table 1.
Baseline characteristics of patients with rheumatoid arthritis treated with pelubiprofen or celecoxib
| Variable | Pelubiprofen (n =77) | Celecoxib (n =68) |
|---|---|---|
| Age (mean ± SD, year) | 54.3 ± 11.4 | 54.8 ± 10.8 |
| Female sex, no. (%) | 69 (89.6) | 62 (91.2) |
| Disease duration (mean ± SD, month) | 100.2 ± 104.2 | 89.8 ± 88.1 |
| ACR functional class | ||
| Class I, no. (%) | 25 (32.5) | 24 (35.3) |
| Class II, no. (%) | 45 (58.4) | 40 (58.8) |
| Class III, no. (%) | 7 (9.1) | 4 (5.9) |
| Class IV, no. (%) | 0 (0.0) | 0 (0.0) |
| DMARD use, no. (%) | 55 (71.4) | 47 (69.1) |
| Prednisolone use, no. (%) | 54 (70.1) | 42 (61.8) |
ACR, American College of Rheumatology; DMARD, disease-modifying anti-rheumatic drug.
P values were determined using the Student t-test or the χ2 test.